IME
-
INCIVEK is well tolerated with commonly used Atripla- and Reyataz-based HIV treatment regimens
Phase 2 study of INCIVEK combination regimen shows 74 percent of people co-infected with hepatitis C, HIV had undetectable hepatitis C virus 12 weeks after treatment ended.
IME | 30 April 2012
-
Gerresheimer acquires Neutral Glass
Gerresheimer AG is committed to growth in the emerging markets. It acquires a majority shareholding in the Indian company Neutral Glass & Allied Industries to help it achieve this aim.
IME | 19 April 2012
-
Gerresheimer wins German Packaging Award for multilayer plastic vials
Gerresheimer has received the German Packaging Award 2011 in the Retail Packaging category for developing vials which offer previously unattained levels of safety for parenteral drugs. Gerresheimer’s multilayer plastic vials unite the best properties of plastic and glass in a high quality packaging for liquid medications.
IME | 12 January 2012
-
Bio-Images and Medimetrics partner to deliver the next generation of smart pill technology
IntelliCap set to speed up clinical research as part of innovative drug delivery package.
IME | 25 October 2011
-
AstraZeneca and Forest Laboratories to initiate phase 3 clinical trials for ceftazidime/avibactam
Treatment for serious Gram-negative bacterial infections.
IME | 18 October 2011
-
Bristol-Myers Squibb and Saladax Biomedical expand collaboration for diagnostic assays for Alzheimer’s disease
Companies will collaborate globally on the development and regulatory approvals for certain diagnostic assays.
IME | 20 September 2011
-
Surviving difficult times
While the global recession has exacerbated fi nancial pressures on biopharmaceutical companies, those pressures create opportunities for the industry to reexamine and revamp the drug development process.
IME | 01 September 2011
-
Dimerix enters into second research program with Takeda Cambridge
Dimerix Bioscience Pty Ltd announced that it has entered into a second research program with Takeda Cambridge Limited. This new program is in addition to the continuing research program announced on 15 April 2010. Under the new agreement, Dimerix…
IME | 14 April 2011
-
New assay provides real-time insights into chemotaxis
EMD Millipore, the Life Science division of Merck KGaA of Germany, announced the introduction of the Millicell µ-Migration Assay Kit. This slide-based platform can be used to visualize and measure the effects of chemoattractants on the migration of …
IME | 30 March 2011
-
Radical change to Alzheimer's management
The first disease-modifying drugs are expected to launch from 2013, radically changing the way Alzheimer’s disease is treated. With the potential to successfully slow or halt the progression of Alzheimer’s, blockbuster revenues are beckoning for …
IME | 26 January 2011
